Search research articles
Contact Us
Filters
Showing results (321-330 of 336) with videos related to
Page
of 34
Sort By:
Frontiers in Public Health
|
October 13, 2025
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Open Journal of Immunology
|
November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Kenneth Blum, Igor Elman, David Han, et al.
Frontiers in Public Health
|
December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Medical Research Archives
|
October 27, 2023
Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
Kenneth Blum, Mark S Gold, Jean Lud Cadet, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Plos One
|
February 6, 2013
Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in Vibrio cholerae targeted by Piper betel derived compounds
Debmalya Barh, Neha Barve, Krishnakant Gupta, et al.
Gene & Protein in Disease
|
May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequences
Kenneth Blum, Abdalla Bowirrat, David Baron, et al.
British Journal of Healthcare and Medical Research
|
May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?
Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 336) with videos related to
Sort By:
Page
of 34
Frontiers in Public Health
|
October 13, 2025
Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Open Journal of Immunology
|
November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Kenneth Blum, Igor Elman, David Han, et al.
Frontiers in Public Health
|
December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia
Kai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Medical Research Archives
|
October 27, 2023
Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
Kenneth Blum, Mark S Gold, Jean Lud Cadet, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Plos One
|
February 6, 2013
Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in Vibrio cholerae targeted by Piper betel derived compounds
Debmalya Barh, Neha Barve, Krishnakant Gupta, et al.
Gene & Protein in Disease
|
May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequences
Kenneth Blum, Abdalla Bowirrat, David Baron, et al.
British Journal of Healthcare and Medical Research
|
May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?
Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Page
of 34